Easy Targets: How Endocrine-Disrupting Chemicals Affect Reproductive Endocrinology
Author: Derek Bagley
Hidden Steroids in Arthritis Supplements Raise Serious Adrenal Concerns
Sriram Gubbi of NIDDK Wins Endocrine Society’s 2025 Endocrine Images Art Competition
Boning Up: National Osteoporosis Awareness and Prevention Month
FDA Files New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
Last month Corcept Therapuetics Incoporated announced that the U.S. Food and Drug Administration (FDA) filed its New Drug Application (NDA) submission for the company’s proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT...
Mind Bending: How Endocrine-Disrupting Chemicals Could Affect Brain Development